References
- Carel JC, Boitard C, Eisenbarth G, Bach JF, Bougneres,PE Cyclosporin delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. J. Autoimmun. 9(6), 739–745 (1996).
- Maini RN, Elliott M, Brennan FM, Williams RO, Feldmann M. TNF blockade in rheumatoid arthritis: Implications for therapy and pathogenesis. APMIS105 (4), 257–263 (1997).
- Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 85(3), 307–310 (1996).
- Robinson WH, Genovese MC, Moreland LW Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis kieum. 44(9), 1977–1983 (2001).
- Chatenoud L, Thervet E, Primo J, Bach JE Anticd3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl Acad. Sc]. USA 91(1), 123–127 (1994).
- Chatenoud L, Primo J, Bach JE Cd3 antibody-induced dominant self tolerancein overtly diabetic nod mice. J. /minuno/. 158(6), 2947–2954 (1997).
- Homann D, Holz A, Bot A et al. Autoreactive cd4+ lymphocytes protect from autoimmune diabetes via bystander suppression using the il-4/stat6 pathway. Immunity 11, 463–472 (1999).
- Abbas AK. Die and let live: Eliminating dangerous lymphocytes. Cell 84,655–657 (1996).
- Chen Y, Inobe J, Marks R et al Peripheral deletion of antigen-reactive T-cells in oral tolerance. Nature 376,177–180 (1995).
- Benson JM, Campbell IKA, Guan Z et al. T-cell activation and receptor downmodulation precede deletion induced by mucosally administered antigen [in process citation]. J. Clin. Invest. 106(8), 1031–1038 (2000).
- Aichele P, Brduscha-Riem K, Oehen S et al. Peptide antigen treatment of naive and virus-immune mice: Antigen-specific tolerance versus immunopathology. Immunity6(5), 519–529 (1997).
- von Herrath MG, Coon B, Wolfe T Tolerance induction with agonist peptides recognized by autoaggressive lymphocytes is transient: Therapeutic potential for Type 1 diabetes is limited and depends on time-point of administration, choice of epitope and adjuvant. J. Autoimmun. 16(3), 193–199 (2001).
- Hanninen A, Martinez NR, Davey GM, Heath WR, Harrison LC. Transientblockade of cd40 ligand dissociates pathogenic from protective mucosal immunity. Clin. Invest. 109(2), 261–267 (2002).
- Maron R, Blogg NS, Polanski M, Hancock W, Weiner HL. Oral tolerance to insulin and the insulin b-chain: Cell lines and cytokine patterns. Ann. NY Acad. Sc]. 778(346), 357 (1996).
- Coon B, An LL, Whitton JL, von Herrath, MG. DNA immunization to prevent autoimmune diabetes. J. Clin. Invest. 104, 189–194 (1999).
- von Herrath MG, Whitton JL. DNA vaccination to treat autoimmune diabetes. Ann. Med. 32,285–292 (2000).
- Wolfe T, Bot A, Hughes A et al. Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent Type 1 diabetes - addition of il-4 increases safety. Eur I Immunol. In press (2001).
- Zang JA, Davidson L, Eisenbarth G, Weiner H. Suppression of diabetes in nod mice by oral administration of porcine insulin. Proc. Nati Acad. Sci. USA 88, 10252–10256 (1991).
- Bot A, Smith D, Bot S et al Plasmid vaccination with insulin b chain prevents autoimmune diabetes in nonobese diabetic mice. J. hrimund. 167(5), 2950–2955 (2001).